Literature DB >> 21119728

Vernakalant.

Dobromir Dobrev, Bashar Hamad, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21119728     DOI： 10.1038/nrd3323

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

Review 1.  New antiarrhythmic drugs for treatment of atrial fibrillation.

Authors:  Dobromir Dobrev; Stanley Nattel
Journal:  Lancet       Date:  2010-03-22       Impact factor: 79.321

2.  Dronedarone.

Authors:  Richard L Page; Bashar Hamad; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

3.  The mechanism of atrial antiarrhythmic action of RSD1235.

Authors:  David Fedida; Peter M R Orth; Janet Y C Chen; Shunping Lin; Bertrand Plouvier; Grace Jung; Alan M Ezrin; Gregory N Beatch
Journal:  J Cardiovasc Electrophysiol       Date:  2005-11

Review 4.  Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.

Authors:  R S Slavik; J E Tisdale; S Borzak
Journal:  Prog Cardiovasc Dis       Date:  2001 Sep-Oct       Impact factor: 8.194

5.  A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

Authors:  Denis Roy; Brian H Rowe; Ian G Stiell; Benoit Coutu; John H Ip; Denis Phaneuf; Jacques Lee; Humberto Vidaillet; Garth Dickinson; Sheila Grant; Alan M Ezrin; Gregory N Beatch
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

6.  Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Peter R Kowey; Paul Dorian; L Brent Mitchell; Craig M Pratt; Denis Roy; Peter J Schwartz; Jerzy Sadowski; Dorota Sobczyk; Andrzej Bochenek; Egon Toft
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12

7.  Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

Authors:  Denis Roy; Craig M Pratt; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Tonny Nielsen; S Lind Rasmussen; Ian G Stiell; Benoit Coutu; John H Ip; Edward L C Pritchett; A John Camm
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

8.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.

Authors:  E Galve; T Rius; R Ballester; M A Artaza; J M Arnau; D García-Dorado; J Soler-Soler
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094
  8 in total
  6 in total

1.  Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.

Authors:  P Stoneman; P Gilligan; P Mahon; R Sheahan
Journal:  Ir J Med Sci       Date:  2017-02-06       Impact factor: 1.568

2.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

3.  Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.

Authors:  Tamer Akel; James Lafferty
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-04       Impact factor: 1.468

Review 4.  The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation.

Authors:  Constanze Schmidt; Jana Kisselbach; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Vasc Health Risk Manag       Date:  2011-03-31

Review 5.  Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.

Authors:  Yukiomi Tsuji; Dobromir Dobrev
Journal:  Vasc Health Risk Manag       Date:  2013-04-23

Review 6.  Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation.

Authors:  Jesús Borrego; Adam Feher; Norbert Jost; Gyorgy Panyi; Zoltan Varga; Ferenc Papp
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.